Posts

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

on

FDA Extends Review of LEQEMBI IQLIK Subcutaneous Starting Dose for Early Alzheimer's Disease

on

FDA Action Alert: Upcoming Decisions on Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai, and Cingulate

on

Eisai Secures FDA Approval for Leqembi Autoinjector for Maintenance Dosing in Alzheimer’s Patients

on

Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology

on

Leqembi's Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

on

Biogen says Leqembi sales are improving slowly following lackluster launch

on

Leqembi wins EU authorization for some Alzheimer's patients, giving Biogen, Eisai a boost over Lilly

on

Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth

on

Australia Rejects Eisai's Alzheimer's Drug Leqembi

on

Australia steadfast on rejection of Eisai, Biogen's Alzheimer's therapy Leqembi

on

Eisai Cuts 121 US Jobs in Strategic Restructuring

on

Eisai Anticipates Growth Acceleration for Alzheimer's Drug Leqembi Despite Slow Initial Uptake

on

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen's Alzheimer's Drug Leqembi

on